Delcath Systems Schedules Conference Call to Report 2021 Third Quarter Financial Results
26 October 2021 - 7:01AM
Delcath Systems, Inc. (Nasdaq:
DCTH), an
interventional oncology company focused on the treatment of rare
primary and metastatic cancers of the liver, announced today it
will host a conference call on Nov 9, 2021 at 8:30 AM Eastern Time
to discuss results for its third quarter ended September 30, 2021.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes
before the beginning of the call.
Date: November 9, 2021Time: 8:30 AM Eastern TimeToll Free:
888-506-0062; Entry Code: 676028International: 973-528-0011; Entry
Code: 676028
The call will also be available over the Internet and accessible
at:
https://www.webcaster4.com/Webcast/Page/2475/43392
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
The company’s proprietary percutaneous hepatic perfusion (PHP)
system is designed to administer high-dose chemotherapy to the
liver while controlling systemic exposure and associated side
effects. In the United States, the PHP system is being developed
under the tradename HEPZATO KIT (melphalan hydrochloride for
injection/hepatic delivery system), or HEPZATO, and is considered a
combination drug and device product regulated by the United States
Food and Drug Administration (FDA).
In Europe, the PHP system is regulated as a Class IIb medical
device and is approved for sale under the trade name CHEMOSAT
Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has
been used at major medical centers to treat a wide range of cancers
of the liver.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
Hayden IR
James
Carbonara(646)-755-7412james@haydenir.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Jul 2023 to Jul 2024